Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...

FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...

AbbVie entered into an agreement to acquire Apogee Therapeutics at a price of $135.11 for each outstanding. The deal is expected to be worth about $10.9 billion and will add Apogee’s entire pipeline ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...